Are the "ounce-equivalents" in the Protein Foods Groups Really Equivalent?
NCT ID: NCT03142737
Last Updated: 2024-09-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
45 participants
INTERVENTIONAL
2017-05-08
2019-05-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
"Ounce-equivalents" in the Protein Foods Group: Benefits of Quality
NCT03179462
Nutrient Synergy in Beef and Stimulation of Protein Synthesis in Elderly
NCT01415973
Protein Source on Plasma Amino Acid Concentrations
NCT03649568
Protein Source, Nutrition Messaging, and Food Intake
NCT03083145
Longitudinal Examination of Metabolic and Behavioral Correlates of Protein Sources
NCT06089460
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Red kidney bean intake
Subjects will consume 1/2 cup of cooked red kidney bean following diet normalization for 3 days.
Red kidney bean intake
Each participant will consume 1/2 cup of cooked red kidney bean
Eggs intake
Subjects will consume 2 cooked large eggs following diet normalization for 3 days.
Eggs intake
Each participant will consume 2 cooked large eggs.
Peanut butter intake
Subjects will consume 2 tablespoons of peanut butter following diet normalization for 3 days.
Peanut butter intake
Each participant will consume 2 tablespoons of peanut butter.
Ground beef intake
Subjects will consume 2 ounces of 90% lean ground beef following diet normalization for 3 days.
Ground beef intake
Each participant will consume 2 ounces of 90% lean ground beef.
Intact beef intake
Subjects will consume 2 ounces of intact beef following diet normalization for 3 days.
Intact beef intake
Each participant will consume 2 ounces of intact beef.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Red kidney bean intake
Each participant will consume 1/2 cup of cooked red kidney bean
Eggs intake
Each participant will consume 2 cooked large eggs.
Peanut butter intake
Each participant will consume 2 tablespoons of peanut butter.
Ground beef intake
Each participant will consume 2 ounces of 90% lean ground beef.
Intact beef intake
Each participant will consume 2 ounces of intact beef.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI from 20 to 29.9 kg/m2
Exclusion Criteria
* History of malignancy in the 6 months prior to enrollment
* History of gastrointestinal bypass surgery
* History of a chronic inflammatory condition or other chronic diseases (Lupus, HIV/AIDS, etc)
* Female subjects who are currently pregnant
* Subjects who are unable to eat animal protein
* Subjects who are unable to stop eating protein or Amino Acid (AA) supplements during the participation
* Subjects who report regular resistance training (more than twice per week)
* Subjects who have concomitant use of corticosteroids (ingestion, injection or transdermal)
* Hemoglobin less than 9.5 g/dL at the screening visit
* Platelets less than 250,000 at the screening visit.
* Any other disease or condition that would place the subject at increased risk of harm if they were to participate, at the discretion of the study physician
20 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Arkansas
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Wolfe, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Arkansas
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
205366
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.